Inovio Pharmaceuticals (INO) 14 Nov 242024 Q3 Earnings call transcript

Good afternoon, ladies and gentlemen, and welcome to the INOVIO Third Quarter 2024 Financial Results Conference Call. [Operator Instructions] This call is being recorded on Thursday, November 14, 2024. I would now like to turn the conference over to Thomas Hong, Manager of Investor Relations. Please go ahead.

Good afternoon and thank you for joining the INOVIO Third Quarter 2024 Financial Results Conference Call.

call today's on me are Dr. Joining President Shea, and Chief Dr. Officer; Executive Jacqui Sumner, Kies, Officer; Chief Peter Medical and Financial Mike Officer; Egge, Chief Chief Officer; Steve Dr. Commercial Morrow, Matthew Translational Sciences. of VP information review corporate XX, will as provide update. as general well quarter call Today's XXXX, and financial ended for our September business a the

conduct Following will segment. a prepared remarks, question-and-answer we

business INOVIO's During we capital will matters. These future medicines future the and the include the regulatory be company. regarding clinical develop readouts along strategic call, developments of performance relate planned events plans platform, which our and with to events submissions, and regulatory DNA clinical making forward-looking to and of and resources statements data timing

replay events shortly as is based is the well the call this materially. be will of press actual statements differ Risk and results website, to within Jacqui which the these We afternoon's that as by refer on link are over and made call available call INOVIO's materially of now be Shea. statements important This our ir.inovio.com, a you those heading the verbally cause CEO, All SEC, we Factors, to and with on the results made identify Dr. expressed time-to-time or factors from found webcast release. can file after to live, being and under this from could company of beliefs today. Actual a documents turn expectations will management concluded. I the President differ as could

call. thank for today's to everyone and afternoon you Good joining

provide XXXX ask near, I towards and medicine of promise on XXXX on importantly, to advancing most then To supporting the highlighting our proposed or stakeholders recently our patients to objectives begin progress responses overall. Today, to commercialization; important T the longer number clinical its data, patients. we've the lead quarter, to ability characterization and Those pipeline; term trial the for been our the candidate, induce presented continuing greater the for thirdly, focused additional mid correspond on this strengthen observed This potential Conference and include: our with, to our conferences, immunological announced eliminate to the International at value extensive deliver continued Phase key scientific detail. have we've RRP cell of surgeries face. DNA we business This in mechanism in two of my to to action has of provide for that benefit secondly, Papillomavirus to I/II and an will including and XXXX firstly, INO-XXXX make progress product reduce colleagues of deliver immunology the advancing objectives week. data overview been

later the well have also was benefit I/II the We in for safety our Mike further this and powerful additional believe details potential will combination on be full and today's for Phase at choice trial that the patients call. RRP Steve provide presented data in We to tolerated and this data it should to have demonstrating XXXX be the recent broadest shown the efficacy preferred number two clinical become approved. XXXX of further conferences. of highlight scientific

continued pre-BLA matters; we mid-XXXX. positive in submission we then, to a targeted August, preparing the BLA FDA. on meeting with our Since in Moving held of have regulatory for

the non-device-related all have end this to expect the by modules for We year. BLA of completed

confident market in treat option deliver new our submission. We for our recently quarterly single-use we identified BLA we call, a during the have device have resolution during issue the we identified testing announced recall the our for required of devastating last as believe for summary, appropriate our this You'll therapeutic XXXX this in to issue In and the to to and an component are making implementation. progress patients disease. remain for good important ability we manufacturing

potential this focus, we financial and XXXX. our completion for our both BLA As resources, our majority are submission of primary of preparing of development, and directing towards commercialization the people is

However, the to even well. important other our are of with XXXX and as of rest significant primary several continued make have pipeline progress our on the focus, candidates mindful we of as potential

to cell with INO-XXXX, this oropharyngeal For and GBM-XXX step a trial. A could in advanced for INOVIO for is European glioblastoma diagnosed anticipate the and with II a our design the America Basser trial positive have inhibitor, Continuing inhibitor trial with as squamous consulted -XX INO-XXXX, XXXX PD-X an the also we've trial continue of patients proposed III in potential cancer. We separate oncology evaluating BRCA regulators in that discussions in the have be newly with combines checkpoint treatment conducting and XXXX Phase Regeneron's alignment Regeneron discussed Center trial Libtayo. of Europe. evaluating with that as next controlled design. appropriate with be dosed patients indicated for in the the trial known ongoing the in XXXX high-risk at regarding PD-X Pennsylvania. GBM Phase North throat mutation FDA at the carcinoma, locally combination LOQTORZI proposed University HPV-XX Previous

to meeting later Ervebo. From pathway earlier-stage this the candidates, FDA-licensed We and by antibodies the to quarter we data discuss what from antibodies monoclonal illustrates peer-reviewed a of platform. design with II to Phase We also reported be DNA-encoded our data Ebola clinical transformational the INO-XXXX Phase potential have vaccine, DNA heterologous year-end. be ongoing a DNA-delivered to will to clinical be first with development publication as monoclonal FDA believe we for submitted and this an an the trial our boost expect scheduled upcoming to medicines believe for the study be I

business to our for strategy of discipline and Finally, a our strengthening success. our is core commitment financial component

overall goals, investments done made cash no operating the equivalents million we've and our $XX.X on in continuing while We we've with with short-term our substantial reduce quarter While third progress to debt. so and closed expenses. cash,

on Now Mike? Mike some for XXXX. the I'll turn it over from new insights to additional data

Jacqui. Thanks,

I surgery. we to both response airways, up from disease the efforts voice can Every wart-like important swallowing, doesn't clinical grow reduction we tolerability presented characterized surgery found immune mount difficulty trial, treatment change insufficient by INO-XXXX bring is and driven develop cause that's current of choking back, of even so review generate the and is we paradigm we to RRP that of the HP permanent to but cycle HPV-XX, unable underlying papillomas to setting In one an infection cells presents an for often address of our I/II the the that People cord loss, have complete compelling clinical the life-changing. That and to disease prevent need both the and severity disease out novel couple the has treatment papillomas, of of to has Phase care and their data the HPV-X potential of the called unchecked. The papillomas at or difficulty T new disease. surgery think breath several patients across patients. to been for for vocal RRP. XXXX of spectrum to standard targeting and or patient again believe it's for benefit XX the risk that damage, symptoms XXXX, is of a observed time what which over the would experience why so or viral conferences RRP papillomas RRP clear respiratory into hard grow small episodes. combination The option a are of clear potential a nonsurgical in with dive CDX HPV-related single papillomas, I patients. cause and antigen-specific speaking a surgery rare tract. be scientific Before weeks, including Designed endless HPV-X reinforcing patients said cytotoxic growth resurgence to a working last our have more shortness central

We body Vaccines of response if saw which intervention summarized its Voice during after after data surgeries and the to be are year potential the October, XX this defined number the patients In at calculated XX experiencing a our of International shows as here. enrolled XX% XXXX the XX when of evidence believe its vast initial providers number or the patients. overall the patients, Conference RRP the no that to prior targeted to or Further, the the responders. the and in dosing preferred and clinical addition, I/II In response a compared significant required and trial, associated decrease a our overall be the supports Fall was majority the generation to we response these interventions was window. as that These patients. This a for payers, number that the the of The growing patients XX% least was the surgical or used that by responders includes of XX% patients of or product of treat INOVIO XX% in immune defined administration and prior by of year XXXX trial, the partial partial in out compared XX efficacy surgeries Conference complete of and safety the response, Society reduction a responders Phase choice approved. At of full year. adding reduction could complete is of rate elimination XX% had surgical for of with healthcare patients. presented past

next treatment-related the safety adverse day patients. On well-tolerated than surgery our counted in was data. you events electroporation reported. was healthcare by the study, can after reported this trial to three to our we in was were every patients design, slide, in events being use reported severity because the treatment-related was overall injection just providers. most pain Grade most matters well-tolerated less patients. No X our with surgery supporting AE Importantly, and in a device common patients, every zero see site XXXX treatment-related than third frequent by adverse of easy greater CELLECTRA that Fatigue also

One a chronic of disease. is treating which for platform cell ability the drive response, T medicine of our the is to particularly DNA viral important core strengths

to now that to to blood scientific having immune HPV shared slide see the in further new for like at tissue ultimately this Virus action can antigen-specific immunology Conference. responses cells those To XXXX, trial. proposed patients recent characterize we and Phase and eliminate analyzed have infiltrate samples week and responses turn T You papilloma need including the mechanism our XXXX, for we the to International from data HPV-infected tissue at on then in the conferences, cell and cells inducing eradicate to the airway the of surgery. I'd blood, travel or I/II this our Papilloma T reduce the

the on papilloma to are very cells tissues reduce microenvironment HPV-X and change airway surgery. the the immunological profiling discovered do and presented. kind clinical data the from was need and that of activation the eradicate action what the two, and into induction, blood include Our baseline, the and just assess do, papilloma exactly to effect. In eliminate the and of combine samples to one, that immunological antigen main number in blood that I form T of from compelling. potential we The HPV-infected of on T tissue impact proposed antigen-specific of the and T to: what goal with study was cell mechanism it of level induce for cells T infiltration HPV evaluate XX; designed to and assessments and steps right We XXXX extensive this was to conducted a Overall, responses key that including of short, individual confirm they the to or infiltrate ability and X takeaways cells cytotoxic points. specificity expansion cell the ultimately very demonstrated

HPV kind right the cytotoxic response, out generation we memory fight RRP and a is the long-lived our antigen-specific see that viral like disease XX with generates In of a vast indicating patients. RRP. which to T responses treatment of INO-XXXX majority immune of -XX research, are important responses to durable the weeks, of chronic for HPV-X First, for cells

Second, where get they to T need newly go. generated cells the to

to cells airway travel blood the the papilloma antiviral and Our data tissue and seen the and that T in resulting shows the inflammatory responses tissue. are from

Fourth, in the detected to pre-existing INO-XXXX. saw the response clones be new immune prior specific the T of of T immune these that seen the We presence responders expansion cells and treatment, are we the saw of of the to clinical cells to we show trial. tissue T to the we meaning blood. seen also have non-responders. tissue both in in not were could T These observed T point majority Third, cells clones. The in in airway XX-week able new treatment at time with benefit emergence cell corresponds and those responses is different new in emergent were with the cells targeted

response that blood, administration microenvironment generate peer-reviewed all We to in that While recent initial of can our in efficacy finally, responses an of at of restrict have additional were XX differed doses. And impact response papilloma scientific journal, and elements appear of elements immune non-responders XXXX. seen. believe the in providing that we found the not in of on have treatment. these potential immunology response magnitude review trial the build through To-date, to have and the to-date, currently forward seen This the these based from we on been patients to a the evidence data looked clinical benefit the to evaluations kinetics an available. is update look clinical at on literature we we when reported under publication the that

potential this is of I point out So new to the would INO-XXXX. like to why important summary, in data so

new of of XXXX. targets cause future generates the RRP component of expands data every disease. that our BLA foremost, have regulatory confirmed XXXX filings. and across spectrum we XXXX the HPV-XX, benefit immunology that disease. The in them and severity and HPV-X vast activates driven and the data majority be other patients also disease that of confirmed the and believe important that and and underlying biological matters. of data XXXX data both to HPV-X The that can cause existing upcoming action First The support submission tell support T of disease. eliminate effectively strains surgery cells clinical us an This that will data the the mechanism Remember -XX the populations

treat in long-term we to I'd on disease. also response a that for Phase the these our severity We over now Commercial of patients we INO-XXXX, game repeat RRP in I/II surgeries like by update important this data a patients it if durability our mention approved, investigating compelling be Chief seen our retrospective believe efforts. regardless addition by completed the provide short, So of year-end. On in anticipate their need Egge, work, goal announcing changer also disease. In note, Steve that clinical our to of be to recently can their to I'll to evidence commercial for study treated immunology data is Steve? able that Officer, RRP study. with have patients turn to for treat an reducing that

everyone. Hello, quarterly see our report, outlined opportunity I on Mike. product profile. XXXX Thanks for compelling significant last I based the At its

strategy patient and receive significant that's for continue and refine on internal to and importantly, external team quarter, consultants we XXXX meet market worked closely the insights we important last in progress we of deep ensuring payer key focused I've go-to-market for of FDA with rooted understanding launch ensure making XXXX. the a a the the Over our to develop and approval. to to stakeholders conducted our have amount and We're plans if most developing of market with needs. We've research physician, develop opportunity a

number of brand reduction the the patients. competitive time. we're we marketplace, in potential product Because the this is month We that We won't hear our difference have that on of repeatedly choices that a meaningful surgery of at of an a makes to a go line as to level, From a patients standpoint, in I U.S. and making from well customer FDA a the key in our strategic to confirmed surgery provide we acceptable significant with ensure payers heard and detail. But disease pricing in even earlier and plan every this did this We're also patient a lives pricing, matters targeting pricing commercial choices areas, single for price making that one for as including of and and access. of are we've at distribution, current do feedback we represent majority into expect segmentation rare XXXX well-differentiated. We've refined the for adoption lives proposed positioning strategic name and in acceptability optimal from product pathways physician experience. from ensure high

of our BLA finally, measure on forecasting ensure including the progress. We're footprint. And strategic brand and in mechanism data as we've decision teams echo also we the of now can most the course, proposed for organization, metrics we'll business to process. We're previously, range imperatives and we've supporting also planned we're developed our Of financial XXXX assumptions, RRP update. confirmed launch-ready will XXXX. the broad commercial be a also XXXX. builds for Chief build-out refining physicians. I'll Kies, of the communicated the plan product And patients end be by that field our action profile launch, include Mike. Peter and during preferred that the -- The a planning out the FDA for to it today commercial planned strengthens the be our could new what belief choice I on of matters my focused a by it and on we've to lean for RRP over Officer, to of and Financial gross-to-net patients and successful product how treat these XXXX's turn compelling and Jacqui a and efficient we've name want in shared

provide like Thanks, quarter financial Today, of Steve. to I'd results third overview the for of XXXX. an INOVIO's

at support expenses. the submit primarily our have to operating BLA noted start efforts, our call, continued to INO-XXXX of and we the control on we goal Jacqui As are advancing To these mid-XXXX. a focused

a third share INOVIO's third third million cash quarter projection third expenses burn in and This diluted of operational and raising fourth third that XX, quarter XXXX. includes loss third per quarter share XXXX third was investments our the or September XX, operating of finished $XX.X total quarter per of of short-term and $XX.X million an the million December from the our into or to cash approximately activities dilutive for XXXX, to compared for loss cash to basic $XXX.X INOVIO in million $XX.X XXXX do take $XX.X compared of net $XX as $X.XX equivalents basic include quarter not quarter the further XXXX. We quarter with any net of XXXX. $XX.X us million $X.XX estimate the of runway We dropped of million ended in for runway net These capital to of million For XXXX. XX% XXXX. estimate undertake. the quarter cash, cash projections XXXX the may

back that, can SEC. And statements release As as a well financial with Form Jacqui. reminder, turn afternoon's to I'll our it as press full filed with find in in our you XX-Q this the over

first from Jay the from [Operator Olson Oppenheimer. Instructions] question line Your of comes

the Congrats for EU are the XXXX regulatory the then your updates And markets? in about in sounds And BLA those a and you What I on making with China any filing progress filing U.S.? Can the outside you're talk all It like lines if U.S. other any the the in Japan, progress could. update I on had or time markets? UK. for major XXXX follow-up,

comment Jay, our where you. on do Hi from other to you are hear nice regulatory to we want filings? Mike, with

Yeah, certainly.

advice was placebo-controlled gain you're European with going have that approval UK, European data UK, mean, to in I to compelling. and basically So need we Union colleagues. their gave the that And they and the to the met to that very be similar needs

rationale of submitting those two in that be But data study only get in complete that, so could would markets. are that an behind was to just prior to Europe. indication And but surgeries, study the have not used also placebo-controlled a to we running going us we that

KOLs to Japan some have and they clearly, spoken of those to yet do ] not out We've But regions. reached [ in have China. We RRP.

so for us are to And areas they of progress. interest

Could you then looking received you data Super physician share physicians that and at that AACR that you any data? may IPVC. feedback helpful. congrats what ultimately presented immunology And on also And are for? great. on new the have Okay,

comment? Mike, do to you want

certainly. Yeah

really characterizing person. more talked Matthew we doing can it, is really think as to clinical have mechanism done -- really So data, and of this basis. we talked just XXXX our scientists clinicians And data. a to I them an the He's of I look, that sciences mean, who's see I that they And great I what Morrow is firstly, of on I action call is also compelling XXXX. gives in it translational think job presented. immunological about confidence -- we've from can that think data the they as

the will very happening our nicely it think ties in nicely clinical to very what's I in actually standpoint. So from also as BLA up link and tie we data an submit just with immunological

the Steinberg's also Professor and we generally, think I shared by the we've in release with have recent the our say, around discussed and Mike, them. KOLs data, field with when very data been evidenced as it press can in quote impressed

going therapeutic for option I this effective an of the Grail of think to Holy them, part after is treat having RRP.

from comes question Citizens of Buchanan line next Your the from Roy JMP.

just the resolve on as Just manufacturing give detail additional on well. envisioning Can maybe XXXX maybe you that to some to you're start issue? steps the

you. hear to Yeah. from nice Roy, Hi

So encountered -- outlined issue the our device. component and single-use steps through the going manufacturing issue resolution through We've we're really summer, and this issue, I I an I pre-BLA ahead gone all issue, that can think that's as implementation. on with take earlier of for meeting. a the just on the our say we the disposable good we And call, progress And in this at of the to making moment. understand to we're need appropriate is

III by if the wrong, Is And that essentially is when Europe, with start think the that? -- for in do enough. do correct? position possible Fair also Is I'm I approved Phase that to that gated Phase resolving was in able correct Europe? think III to Okay. device you you the in And manufacturing might issue. it XXXX the then be you me And right, Mark. be first CE might start a this

Roy. question, great a that's Yeah,

you to about do Europe on device So yes, as XXXX? in well. around is want talk III XXXX regulatory interactions this for our that starting Phase trial issue dependent resolving Mike,

Yeah.

the the the cancer design continues as and We're we've incidence in gain in of is with throat EMA, from the to So rise. we've as previously disease that for and high-income alignment FDA countries, mean, said, that a propose we global HPV to expecting I discussions got most we're study. alignment feedback on

very like regions. would this both much to run study we in So

feedback, at call. that So awaiting we then next we're can you update anxiously on the and that

from of Sudan Your next the Stephens. question line comes Loganathan from

Quick question competitive the landscape. on

how XXXX, that panning think I see competitive the product? how you do out? differ And do Precigen you from landscape

that's great Yeah, a question.

our of believe has saying, very off we clinical the right across on believe immunology So idea XXXX, in discussed to it basis a and that, patients Mike by HPV-X across start how drive we us the really for both for as in benefit in sort that. very of that we're preferred ability to the new reasons I'll and all, product earlier choice the and call, of think the disease profile we this severity first doing of product I profile And that be clear XXXX gives confident physicians. -XX. And the is why see exactly of

is Precigen's gorilla is based product adenovirus. around DNA So a medicine. a XXXX

to So And difficult different data to conducted a way. deliver gene in it's very two because the adenoviral using were trials compare vector an it's sequences. clinical the the

to matters surgery every believe we XXXX, patients. for So

somewhat trial zero. counted think every prior day And assessment that surgery and the to allowed different in after period. surgery a efficacy Precigen I we design So conjunction, used of scoping

want approach. candidates? those very a products, that out anything two the else took really we you So of sort differences between add to Mike, calls product different to

think I regimen. different mean treatment fundamentally, I very they're

removal While proactive week XX treatment their week X X papilloma regimen and that scoping is we doses, both visualized. any includes have and of at

matters. point. surgery if time significant and week sort XX X surgeries those to And back number go every of They message see week a you did patients, from at we've of so the heard

it. how we also and other take up do that's think treatment perceive to so sort And going impact might of how patients the physicians

consider table? If question. I ask manufacturing? mold the would Is plastic can the on manufacturing another The changing you that --

Yeah.

mentioned single-use disposable proposed we've we implement we're and injection molded that identified here component we're question to resolution. working the the closely with to -- the your I the component issue So I to I the guess we've what with And relating manufacturing of mentioned, a doing relates And up that issue device. earlier very is of manufacturer as resolution path. come believe

we're planning We're manufacturer moment, closely at the So on with changing very that our manufacturer. not to working resolution. implement existing

of comes Cheng Liang Jefferies. question Your next from line the from

Liang Jefferies. is Roger Cheng This for from

about guess my XXXX. question I So first also

same also the XXXX, confirmatory study? thinking And idea the or Just immunology redosing the do implement any about of wondering any about that study. about design you still you in then Are envision trial?

So I just the non-responders? versus And wonder anything there? at responders have noticed you looked you

that's a great Yeah, question.

confirmatory about design Mike, trial. on we do to why we and that want you have So outline our of it? talked the decided design

absolutely. Yeah,

with trial they had So placebo-controlled it in year, to indication Phase if used to what agency, two the the I/II in be study very discussions the preceding made then have clear our we we surgeries similar of wanted an in a study. to

are And about comments along patients. those just randomization going so we We're particularly very have to then feedback study. with a confident to my XXX isn't to X:X previous patients large run the clearly follow study, a Europe, going it efficacy we've from the randomized received seen. This And to a with in out. respect sense be and made clinical that we've

out going have plasmid had rationale days. to that XXX XXX a And for the and at element previous into include redosing present. this to efficacy HPV-X-only over had with patients aren't treated have an We that study we is

they Phase for So on will end than the a follow-up have we the -- discussion keen longer us we that agency, of I/II well in had were the hopefully year. for to with that to by in we'll retrospective previously the us was study. motivation the also study our run And report

the we of XXXX. really think period characterize longer benefit a you to need do time of So

confirmatory way we the why study have. So we design our picked that's

just a detail. then the I'll bit And briefly Mike. immunology on more and I'll Thanks data, fill in comment ask to Matthew

at non-responders, samples. of versus responders we we absolutely, looked two yes, and looked sets So at

peripheral were of trial. And we the throughout then the blood set duration first collected also samples samples. had of tissue that The samples we

add prior a paired want So do treatment patients we same difference were that other some then from to at in with from location. responses clinical anatomical saw believe XX-week the But tissue these samples in taken that responders time benefit. samples and versus period. of same non-responders the the corresponds to from the and and you in And we airways Matthew, here? immune taken we the And saw comments kinds jump

Sure. Good afternoon.

and Jacqui of of the in with of interferon observed. gamma that and will slightly the the interferon alpha publication yes, overall the has than different what non-responders cells, and within responses described to those assessments tissue cells inflammatory of that So addition functionality that in some T respect the of all the responders response further And being T of responses degree are is of be these infiltration forthcoming. is mentioned, just to

for for ongoing what's wondering XXXX, very EU regulators, you trial guess with just That's -- needed I conversation the the initiation? also helpful. the before

do comment Mike, to Yes. on want that? you

Yeah.

obviously, mean, of I is XXXX. used the of So global interaction this how in with study previously, to designed think overall we've I actually gain And design. said KOLs alignment strategic as the intent we've the we purpose

representation And good we from Europe. have so a very

And the a so the we're then And alignment. just trial optimistic put that application patients. part we clinical practical recruiting we started can have to is obviously that would gain before we into EMA

from Wainwright. line comes question of Chen next from H.C. Your Yi the

and BLA the already you in on little for curious Eduardo was for clarity bit more how Yi. on a timeline could I trial if with for the [ you confirmatory submission fits that XXXX is This expressed. that initiating ] offer the

question, Eduardo. Great Yeah.

submission. BLA as told our of And the review submission, part that start start confirmatory rolling So as our targeting us of mid-XXXX. BLA we expecting that We to FDA priority need to clearly ahead on our submission. very we're call, request BLA have that commencing we're stated trial we to for submission need --

is So mid-XXXX. what I can today tell you

that we are that a Maybe -- opposite And rationale have We, I'll confirmatory bit end color been their needed their commence study. very forthcoming add little not sponsors around however, is delivering that at activities. in We has clearly, for the often the our said FDA spectrum. of studies. to of

We identified. have our all almost sites

We are sites. contracting with

active We have IRB submissions.

So we in good confirmatory will our the that commitment position be on to to of study very delivering a demonstrate agency.

great That's Mike. you, Thank Yeah. point. a

really in worked that that centers conducted trial at I Phase leveraged the think U.S., clinical our from we've sites, are forefront I/II the ] experience also release we [ X across of treating we study where our RRP. different

helpful. very as across sites working of well experience been that think I different has So

question Renza comes the from of Markets. line RBC next from Your Gregory Capital

Precigen you Anish the such site translates Hi team. CELLECTRA when if how rapidly CELLECTRA how they device, support AEs physician think resolved you and being as the market and your and about the given duration thinking remind the about the to the patient close how already which would a the prospects us on could the injection you time were XXXX expectations XXXX On this device. And launch? fatigue, also a with market the uptake just commercial Greg. strategy, in It's go-to-market using of and you of competitor the approach by launch, pain could strategy, as reporting and and are after on maybe for suggesting

Thanks, Anish. Great questions.

call our during of talked in the about Mike, in of how profile I about saw the terms talk can you safety think, adverse XXXX, resolved? event as So we terms and Mike combined data; quickly that they

absolutely. Yeah,

going is on procedure. have around physician pain the should be patient data injection our site time what of the were you XX administration XX -- show event. report is the the whole, So the as rollout had in of of patients out electroporation look XX patients those a we adverse of the population to when clearly, any studies of expect, we treatment-related educate this a new reported -- the the grading of at how that of X-, of And part only XX% because injection we only other was treatment-related as explaining that. And should -- The really rest those about entire after were [indiscernible] associated From adverse patient a pain. that really in the off that a X. falls Grade device sort fact, events the rest Grade from perspective, site XX-minute with X frame. one

the it around of is unknown. half So

have to and that So any carefully know hopefully in expectation to we'll level adverse pain. very further to materials able as with be for to come site market, we expect. will that having the electroporation place injection history events diminish says And associated diminish patient what of that

very very adverse these events also resolve certainly, important that use. tell treatment the hear They Mike, are And it's think easy from transient. us healthcare the providers to I note, tolerable patients is very is the that very very to device and is we rapidly.

very a resolution patients that impact particularly be important. of RRP, think, having devastating where to is the in a we it's on going AEs So really like rapid those disease

that go and does 'XX profile? your Anish, answer on strategy. the Yeah. So the we around launch to go-to-market can XXXX questions And maybe then

to XXXX profile limited in it it's patients more this earlier will hand from So of and that as we a product seen I'll detail. to-date. product compelling And discussed in I bit believe also enable that only over we've on of -- on physicians. the preferred call, the expand the data has Precigen to a But to become majority Steve choice for

published the We full from data haven't package seen yet cohort. second the

think I difference And interesting. very approaches, I it's interested we'll going see treatment when to be and are think, data regimens in that be So to the very published. two the

duration our to this data to able that think is to we year be announce also expect later be on going I important.

to view? So provide do your you point Steve, want of

Yeah.

regardless, engaging approval in as as know We on don't data account see the managers that they MSLs before We'll we based unfold. we've kind to seen ahead Precigen national approval, have a do. will things think of out got product that we far. can we health well plans So so of well-differentiated of will. be necessarily the we've But how ahead market do plan which

the be surgeries. we'll what focused But on. and know the need certainly around we tremendous burden in that's there's unmet market So

As we've matters. every talked about, surgery

we're there XXXX. we case as force we're So making out as will for full soon able, the be soon as approved, in as

comes question JMP. from next Citizen Roy of Buchanan Your from line the

of look after it that But guess confirmatory is XXXX, to you and of sequenced be run that the It I think just trial going plan was to separate redosing trial? of at I about redosing going actually run in trial most correct? Do you answered the or with you're the to conjunction conclusion it. a to

about Yeah. redosing that you want to Mike, talk do approach?

Yeah, absolutely.

So we've commercial in always thought be the work that would redosing patients.

cells. that all while, the potentially work at questions talk and a can one of the will But practically after And There's going that are commence at So we sort can be post will this look lot of around complete possible interesting as that we'll I week. that been launch. continued infected take those to scientific is And as a thinking launch. soon could maintain IPVC as HPV we responders we through dosing. of think commercial that that commence you actually eliminate

no will for turn are the to I closing Shea at Jacqui questions remarks. now There Please this further call time. back go ahead.

adds with truly Thank discussed have for patients the growing devastating treatment been that the to evidence you. The of continues immunology potential who data today of RRP. we've new XXXX effects to paradigm of transform the living body to a illustrate that

announcing submitting mindful are on patients of preparing same meet new those to should candidates going data, the and BLA support as possible as to strengthen including our of remain key ahead, We the quickly work ways as we at the focused and immunology we new forward. durability, milestones moving end sheet other to our advancing our XXXX, we're be approval. At evaluating time, publishing the key launch-ready to receive balance

in we your Thank wrap I'm to everyone. made we've of for the we attention good and months, the momentum As year just this proud going ahead. up plan keep XX evening progress year, short you important and in that

you gentlemen, conference and participation. Ladies concludes this call. for your Thank today's

You now disconnect. may